Consun Pharmaceutical Group Limited
Research Consun Pharmaceutical Group Limited (1681.HK) on Bullrun: market cap HKD 13.14B, P/E 10.2, dividend yield 4.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1681.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 13.14B
- P/E10.2
- Dividend yield4.9%
- Financial periodFY2025
- RevenueCNY 3.42B
- Revenue growth15.2%
- Net incomeCNY 1.08B
- Free cash flowCNY 1.14B
- Gross margin78.0%
Valuation Snapshot
latest market cap is HKD 13.14B; P/E is 10.2; dividend yield is 4.9%.
Peer valuation comparison
Latest P/E is 10.18x versus a Healthcare sector median of 21.69x (53.1% below).
Latest dividend yield is 4.86% versus a Healthcare sector median of 2.41% (101.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.42B | CNY 1.08B | CNY 1.14B | 78.0% | 1.26 | CNY 1.23B | CNY 212.92M | CNY 4.54B |
| FY2024 | CNY 2.97B | CNY 910.46M | CNY 977.99M | 75.6% | 1.09 | CNY 2.91B | CNY 267.17M | CNY 4.10B |
| FY2023 | CNY 2.59B | CNY 784.53M | CNY 766.41M | 74.2% | 0.98 | CNY 2.75B | CNY 511.53M | CNY 3.63B |
| FY2022 | CNY 2.34B | CNY 682.91M | CNY 896.09M | 75.3% | 0.86 | CNY 2.45B | CNY 460.18M | CNY 3.15B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 13.14B | 10.2 | 5.0% | 0.78 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.78 HKD, yield 4.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.63 CNY |
| FY2024 | 0.9 CNY |
| FY2023 | 0.45 CNY |
| FY2022 | 0.2 CNY |
| FY2021 | 0.3 CNY |
About Consun Pharmaceutical Group Limited
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Consun Pharmaceutical Group Limited's market cap?
Consun Pharmaceutical Group Limited's market capitalization is HKD 13.14B.
What is Consun Pharmaceutical Group Limited's P/E ratio?
Consun Pharmaceutical Group Limited's price-to-earnings (P/E) ratio is 10.2.
Does Consun Pharmaceutical Group Limited pay a dividend?
Consun Pharmaceutical Group Limited has a dividend yield of 4.9%.
What does Consun Pharmaceutical Group Limited do?
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical.